Breast and prostate cancer

Aspects concerning co-morbidity; patterns of drug use, long-term survival

The aim of this project was to study aspects of co-morbidity; patterns of use of prescribed drugs; and long term survival in patients with advanced disease at diagnosis.

Project description

Background: Reasons for non-adherence to management guidelines for breast- and prostate cancer are not always clear, but may be attributed to concomitant disease. Also, co morbidity burden may represent one explanation for social gradients in survival. - Little is known about patterns of drug use in cancer patients. - Long term survival in cancer patients with advanced disease raise questions about diagnostic accuracy and whether these patients have special characteristics.

Material: Clinical Quality Registers on Prostate and Breast Cancer, the Register of Prescribed Pharmaceuticals and other databases.

Project leader


Mats Lambe

Phone: 08-524 861 64
Organizational unit: Department of Medical Epidemiology and Biostatistics (MEB), C8

Project period: 2009-2014
Main financing: The Swedish Cancer Society, the Swedish Council for Working Life and Social Research.


Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden.
Berglund A, Garmo H, Tishelman C, Holmberg L, Stattin P, Lambe M
J. Urol. 2011 Mar;185(3):833-9
Impact of comorbidity on management and mortality in women diagnosed with breast cancer.
Berglund A, Wigertz A, Adolfsson J, Ahlgren J, Fornander T, Wärnberg F, et al
Breast Cancer Res. Treat. 2012 Aug;135(1):281-9

Prostate cancer